

Dimer-monomer equilibrium of SARS-CoV-2 main protease as affected by small molecule inhibitors: a biophysical investigation

Lucia Silvestrini

Marche Polytechnic University

Norhan Belhaj

Marche Polytechnic University

Lucia Comez

National Research Council

Yuri Gerelli

Marche Polytechnic University

Antonino Lauria

University of Palermo

Valeria Libera

University of Perugia

Paolo Mariani

Marche Polytechnic University

Paola Marzullo

University of Palermo

Maria Ortore

Marche Polytechnic University

Antonio Palumbo Piccionello

University of Palermo

Caterina Petrillo

University of Perugia

Lucrezia Savini

Marche Polytechnic University

Alessandro Paciaroni

University of Perugia

Francesco Spinozzi (✉ f.spinozzi@univpm.it)

Marche Polytechnic University

Keywords: COVID-19 pandemic, SARS-CoV-2, SAXS

Posted Date: January 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-135283/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on April 29th, 2021. See the published version at <https://doi.org/10.1038/s41598-021-88630-9>.

Dimer-monomer equilibrium of SARS-CoV-2 main protease as affected by small molecule inhibitors: a biophysical investigation

Lucia Silvestrini¹, Norhan Belhaj¹, Lucia Comez³, Yuri Gerelli², Antonino Lauria⁴, Valeria Libera⁵, Paolo Mariani², Paola Marzullo⁴, Maria Grazia Ortore², Antonio Palumbo Piccionello⁴, Caterina Petrillo⁵, Lucrezia Savini¹, Alessandro Paciaroni^{*5}, and Francesco Spinozzi^{†*2}

¹Marche Polytechnic University, Department of Life and Environmental Sciences and New York-Marche Structural Biology Center (NY-MaSBiC), Ancona, 60131, Italy

²Marche Polytechnic University, Department of Life and Environmental Sciences, Ancona, 60131, Italy

³CNR-IOM c/o University of Perugia, Department of Physics and Geology, Perugia, 06123, Italy

⁴University of Palermo, STEBICEF Department, Palermo, 90128, Italy

⁵University of Perugia, Department of Physics and Geology, Perugia, 06123, Italy

*alessandro.paciaroni@unipg.it, f.spinozzi@univpm.it

ABSTRACT

The maturation of coronavirus SARS-CoV-2, which is the etiological agent at the origin of the COVID-19 pandemic, requires a main protease M^{pro} to cleave the virus-encoded polyproteins. Despite a wealth of experimental information already available, there is wide disagreement about the M^{pro} monomer-dimer equilibrium dissociation constant. Since the functional unit of M^{pro} is a homodimer, the detailed knowledge of the thermodynamics of this equilibrium is a key piece of information for possible therapeutic intervention, with small molecules interfering with dimerization being potential broad-spectrum antiviral drug leads. In the present study, we exploit small angle x-ray scattering (SAXS) to investigate the structural features of the SARS-CoV-2 M^{pro} monomer-dimer equilibrium, by revealing the corresponding equilibrium dissociation constant and the associated thermodynamic parameters. SAXS is also used to study how the M^{pro} dissociation process is affected by small inhibitors selected through combinatorial design. Our results show that a clear picture connecting the ability of inhibitors to disrupt the M^{pro} dimerization with the loss of catalytic activity cannot be provided, thus highlighting the possible role of allosteric effects for the regulation of M^{pro} functionality.

Introduction

The COVID-19 pandemic is the ongoing worldwide health emergency caused by the coronavirus SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2).^{1,2} Coronaviruses (CoVs) are enveloped positive-stranded RNA viruses; once the virion gets into the cell, the single-strand RNA translates into two overlapping polyproteins, termed pp1a and pp1ab, which mediate viral replication and proliferation. The virus maturation involves a highly complex cascade of proteolytic processing events on these polyproteins: most cleavage events are ruled by a nonstructural protein, the CoV main protease (M^{pro} , also known as 3CL^{pro}), a three-domain (domains I to III) protein.³ The enzyme shows first autolytic cleavage from pp1a and pp1ab, then starts processing the two polyproteins at no less than 11 conserved sites.³

Because of this mechanism of action, inhibiting M^{pro} might lead to an attenuation of the viral infection. Indeed, this enzyme is a very attractive target for anti-CoV drug design: the M^{pro} sequence is highly conserved among various CoVs,⁴ as mutations of M^{pro} turn out to be often fatal for the virus.⁵ Thus, the risk of mutation-mediated drug resistance is very low and inhibitors will display broad-spectrum antiviral activity. In addition, M^{pro} inhibitors are unlikely to be toxic because human proteases have different cleavage specificity. A second point should be however considered: the published X-ray structures of SARS-CoV-2 M^{pro} , obtained both in the presence and in the absence of inhibitors,^{6,7} revealed that two M^{pro} monomers form a functional active homodimer, as already detected in different coronaviruses,³ which share with SARS-CoV M^{pro} almost all the amino-acids involved in the dimerization. In such homodimer, the two monomers are arranged almost perpendicular to each other⁷ and each monomer comprises the catalytic dyad His41-Cys145 and the substrate-binding site located in a cleft between domains I and II. Domain III, which contains five α -helices arranged into a globular cluster, is directly involved in

controlling the dimerization of M^{pro} mainly through a salt-bridge between Glu290 of one monomer and Arg4 of the other.⁸ Quite remarkably, while individual monomers are enzymatically inactive, M^{pro} is active in the dimeric form. The structural reason behind the functionality of the dimer is probably due to the interaction of the N-finger of each of the two monomers with Glu166 of the other monomer, which establishes the shape of the so-called S1 pocket of the substrate-binding site.⁹ To approach this interaction site, the N-terminal amino acid residues are squeezed in between domains II and III of the parent monomer and domain II of the other monomer.⁷

According to these considerations, two different strategies have been considered for the development of therapeutic agents: first, direct inhibition of the catalytic site by using molecules targeting the substrate binding pocket; second, attenuation of the catalytic activity by using inhibitors targeting the dimerization site. The second alternative is strictly related to the M^{pro} equilibrium between dimers and monomers in solution. The thermodynamic equilibrium of M^{pro} dissociation process has been recently studied by analytical ultracentrifugation. Sedimentation velocity experiments provided a value of about 2.5 μM for the apparent dimer dissociation constant K_D .⁷ However, a more recent estimate by mass-spectrometry based assays established for K_D a much lower value of $0.14 \pm 0.03 \mu\text{M}$, indicating that M^{pro} has a stronger preference to dimerize in solution than expected. In the case of SARS-CoV M^{pro}, an even wider discrepancy among the different estimates of the dimer-monomer dissociation constants has been observed, with the values of K_D provided by various experimental techniques falling in a range from $230 \pm 30 \mu\text{M}$ ¹⁰ down to $0.19 \pm 0.03 \mu\text{M}$.¹¹ In the light of the above mentioned uncertainty on the K_D value, we decided to further investigate the SARS-CoV-2 M^{pro} dimer-monomer equilibrium. The study was performed both in the absence and in the presence of a set of in-silico selected small inhibitors, whose activity was spectroscopically assayed, in order to simultaneously test their therapeutic potential with respect to dimerization inhibition. The analysis, focused on the characterization of the large-scale structural features of SARS-CoV-2 M^{pro} in solution and on the assessment of the effect of small inhibitors on the dimer-monomer equilibrium, was based on synchrotron Small-Angle X-ray Scattering (SAXS) measurements, integrated by Circular Dichroism (CD), Molecular Docking and Fluorescence experiments.

Results

As the dimerization process is a pivotal key for the biological activation of the SARS-CoV-2 M^{pro}, several therapeutic strategies against COVID-19 are based on inhibitors acting also (or only) at the M^{pro} dimerization interface.^{6,12,13} In order to evaluate the effects of potential inhibitors targeting both the catalytic and dimer dissociation, we have first derived the thermodynamics parameters controlling the M^{pro} dimer-monomer equilibrium in solution by SAXS and CD spectroscopy techniques. Subsequently, we have investigated by SAXS experiments the M^{pro} dimerization in the presence of a series of potential inhibitors, selected from an *in-house* database containing commercial and synthetic compounds. Activity assays were also performed to correlate the M^{pro} activity to dimerization inhibition.

M^{pro} dimerization and thermal stability

The dimer-monomer equilibrium of SARS-CoV-2 M^{pro} has been investigated at different protein concentrations by performing in-solution SAXS experiments in the temperature range between 15° and 45° C and far-UV CD measurements at room temperature. Far-UV CD spectroscopy was also used to study the M^{pro} thermal stability, monitoring the unfolding transition between 10° and 80° C.

SAXS

SAXS data of SARS-CoV-2 M^{pro} recorded at the B21 beam-line of the Diamond Synchrotron (Didcot, UK) at different protein concentrations and temperatures are shown as log-log plots in Fig. 1, top panels. We have assumed that SAXS curves arise from a system of interacting M^{pro} monomers and dimers, according to the thermodynamic equilibrium dissociation process given by the relationship:



The corresponding equilibrium dissociation constant is

$$K_D = \frac{[\text{M}_1^{\text{pro}}]^2}{[\text{M}_2^{\text{pro}}]} = \frac{2Cx_1^2}{1-x_1} = e^{-\Delta G_D/(RT)}, \quad (2)$$

where C is the total molar concentration of monomers, x_1 is the molar fraction of proteins that remain in the monomeric state, ΔG_D is the dissociation Gibbs free energy change, R is the universal gas constant and T the absolute temperature. To note, equation 2 can be solved in terms of x_1 ,

$$x_1 = K_D \frac{\sqrt{1+8C/K_D}-1}{4C}. \quad (3)$$




Figure 1. SAXS data and fits. **Top panels:** SAXS experimental data of SARS-CoV-2 M^{pro} without inhibitors and best theoretical fits obtained by GENFIT software¹⁴ (solid black and white lines). Each panel reports a dataset obtained at the same temperature. **Bottom panels:** SAXS data of M^{pro} with inhibitors at different concentrations and temperatures. Each panel reports curves at the same temperature. Red, green, blue, orange, dark-green, cyan and magenta refers to inhibitor **1**, **2**, **3**, **4**, **5**, **6** and **7**, respectively. Thin and thick lines refer to inhibitor concentrations of 30 and 60 μM , respectively. Subsequent curves are multiplied by a factor 3.0 for clarity. Solid black and white lines are the best fits obtained by GENFIT.

According to classical thermodynamics, the temperature dependence of ΔG_D is

$$\Delta G_D = \Delta G_D^\circ + (\Delta C_{pD} - \Delta S_D^\circ)(T - T_o) - \Delta C_{pD} T \log \frac{T}{T_o} \quad (4)$$

where $\Delta G_D^\circ = -RT_o \log K_D^\circ$ is the dissociation Gibbs free energy at the reference temperature $T_o = 298.15$ K (K_D° being the associated equilibrium constant), ΔC_{pD} is the change of the constant pressure heat capacity upon dissociation (here supposed independent on T) and ΔS_D° is the dissociation entropy at T_o .

The macroscopic differential scattering cross section, which is the experimental information provided by a SAXS curve, for a system of interacting monomers and dimers can be written as

$$\frac{d\Sigma}{d\Omega}(q) = N_A \kappa C_N P(q) S_M(q) + B, \quad (5)$$

N_A being Avogadro's number, κ an unknown fraction of the nominal protein molar concentration C_N ($C = \kappa C_N$), B an arbitrary flat background that takes into account possible uncertainties in the determination of transmissions of proteins and buffers samples. $P(q)$ represents the average form factor of the system

$$P(q) = x_1 P_1(q) + \frac{1}{2} (1 - x_1) P_2(q), \quad (6)$$

where $P_j(q)$ stands for the form factor (which is the orientational average of the excess squared X-ray scattering amplitude) of the M^{pro} monomer ($j = 1$) or dimer ($j = 2$). We have calculated $P_j(q)$ from the the crystal structure of SARS-CoV-2 M^{pro} dimer recently determined⁷ (PDB code 6y2e) considering one chain ($j = 1$) or both chains ($j = 2$) by means of the SASMOL

method.¹⁵ This method takes into account the contribution to the scattering due to the hydration water molecules around the protein, whose positions are found by embedding the atomic structure in a tetrahedral close packed lattice. For SARS-CoV-2 M^{Pro} monomer and dimer, 726 and 1243 hydration water molecules have been respectively calculated, suggesting that for the dimer formation about 200 water molecules are removed from the hydration shell of both monomers. Hence, the water molecules attributed to each monomer decrease from 726 to 621 upon M^{Pro} dimerization. This suggests that the dimerization process is accompanied with slight structural changes reducing the average area accessible to solvent. The $S_M(q)$ term in equation 5 is the so-called “measured” structure factor, which describes the long range intermolecular interactions among all the particles in solution. For a sake of simplicity, here we consider a unique effective structure factor that takes into account monomer-monomer, monomer-dimer and dimer-dimer interactions. Considering that at low q all the experimental scattering curves (Fig. 1 top panels) show a positive deviation from a Guinier trend, indicative of the prevalence of protein-protein attraction with respect to repulsion, we have approximated the structure factor by the one of fractal distribution of inhomogeneities developed by Teixeira,¹⁶ whose main parameters are D , the fractal dimension of the aggregates, r_0 , the effective radius of the aggregating protein molecule and ξ , the correlation length, which can be interpreted as the average size of the aggregates (see equations 10, 11 and 12).

The above described model, which combines SARS-CoV-2 M^{Pro} thermodynamic and structural features, has been adopted to simultaneously analyze the whole set of the SAXS curves shown in Fig. 1, top panels. Fitting parameters shared by all the curves are K_D° , the dissociation equilibrium constant at T_\circ , ΔC_{pD} , the constant pressure heat capacity upon dissociation, ΔS_D° and the dissociation entropy at T_\circ . Another parameter considered unique for all the curves is the relative mass density of the hydration water (in general higher than 1), d_h , which is taken into account in the SASMOL method.¹⁵ The common fitted parameters are shown in Table 1, while all the other fitted parameters are reported in Supplementary Table S1.

K_D°	(μM)	7 ± 1
ΔC_{pD}	($\text{kJ mol}^{-1} \text{K}^{-1}$)	1.7 ± 0.7
ΔS_D°	($\text{J mol}^{-1} \text{K}^{-1}$)	50 ± 20
d_h		1.100 ± 0.006

Table 1. Thermodynamic parameters resulting from the global fit of SAXS data for SARS-CoV-2 M^{Pro} without inhibitors at different temperatures and concentrations.

The most important parameter obtained by the simultaneous fit of SAXS data is the dissociation constant K_D° , which resulted equal to $7 \pm 1 \mu\text{M}$, in good agreement with the value obtained by Graziano et al.¹⁷ on the very similar main protease from SARS-CoV. The corresponding dissociation Gibbs free energy is $\Delta G_D^\circ \simeq 30 \text{ kJ mol}^{-1}$, a value quite similar to the one observed for the β -lactoglobulin dimer dissociation at neutral pH.¹⁸ Regarding the dissociation entropy, we have obtained a positive value, $50 \pm 20 \text{ J mol}^{-1} \text{K}^{-1}$, but meaningfully smaller in respect to the one observed in the above mentioned β -lactoglobulin case.¹⁸ It should be noticed that in a dissociation process, many factors other than translational and rotational motions contribute to a positive dissociation entropy and it is difficult to separate them. One such factor is, without doubts, the removal of about 200 hydration water molecules from the monomer-monomer interface when the dimer is formed. The change of the heat capacity at constant pressure upon dissociation resulted positive and large. This parameter indirectly describes the monomer-monomer interface, as it can be attributed to the hydration and correlates with the interface size.¹⁹ When dissociation heat capacities are positive and large, temperature meaningfully increases monomer-monomer affinities. This is our case: the M^{Pro} large dissociation heat capacity might be directly correlated with the SARS-CoV-2 infective efficiency as a function of temperature. However, a further investigation on the monomer-monomer interface area and its relationship with the dissociation heat capacity²⁰ requires further calorimetric experiments in order to obtain lower estimation errors. Finally, the relative density of the hydration shell is slightly larger than one, in agreement with previous literature results on globular proteins.^{21–23} The determination of the thermodynamic features of the dimer-monomer equilibrium of M^{Pro} in conditions quite similar to those found *in vivo* is a fundamental step to investigate the effects of drugs aimed to inhibit dimerization and underlines the importance to further investigate M^{Pro} monomer-monomer interface by in-solution techniques.

Far-UV CD

To provide further insights on the dimer-monomer equilibrium, we have measured the far-UV CD spectra of M^{Pro} at three different concentrations, as shown in Fig. 2, left panel.

At the higher concentration of $16 \mu\text{M}$, the ellipticity shows a minimum wavelength λ^{min} at about 221 nm and a shoulder centered at about 208 nm, which are typical of proteins with α -helical and β -sheet content,^{24,25} fully consistent with the structural features of the SARS-CoV-2 M^{Pro},⁷ in agreement with CD measurements of the same enzyme²⁶ and of the very much similar SARS-CoV M^{Pro}.²⁷ As concentration decreases, λ^{min} shifts towards lower values, thus reporting an increase of the β -sheet component at the expense of the α -helical content.²⁴ Such an effect is related to the fact that M^{Pro} monomer and dimer





Figure 2. CD data and fits. **Left:** far-UV CD spectra of SARS-CoV-2 M^{pro} at three different concentrations. Inset: position of the minimum of the spectra as a function of the concentration (red circles). The continuous line represents an estimate of the minimum position based on equation 7. Results from the fit are: $\lambda_{\text{mon}}^{\text{min}} = 216.4 \pm 0.1$ nm and $\lambda_{\text{dim}}^{\text{min}} = 222.9 \pm 0.1$ nm. **Right:** Thermal melting of the SARS-CoV-2 M^{pro} followed by monitoring the far-UV CD signal at 221 nm. The continuous line results from the theoretical fitting model arising from equation 8.

have different secondary structure components. The λ^{min} trend can be described in terms of the dimer-monomer equilibrium through the following expression,

$$\lambda^{\text{min}} = x_1 \lambda_{\text{mon}}^{\text{min}} + (1 - x_1) \lambda_{\text{dim}}^{\text{min}} \quad (7)$$

where we fixed $K_D = 7 \pm 1$ μM as estimated by SAXS, while $\lambda_{\text{mon}}^{\text{min}}$ and $\lambda_{\text{dim}}^{\text{min}}$ are the minimum wavelength parameters corresponding to the monomer and the dimer spectra, respectively. As shown in the inset of Fig. 2 (left panel), the trend of the λ^{min} values is fitted in an excellent way with equation 7.

The thermal stability of the M^{pro} has been characterized by monitoring the signal at 221 nm of the M^{pro} sample at 16 μM concentration, which mainly consists of dimers. The rather sharp transition we have obtained is shown in Fig. 2 (right panel) and clearly suggests a two-state model, where the dimer unfolds and yields two random-coil monomeric chains:



Considering the scheme 8, if we hypothesize that the dimer can unfold to two random-coil monomeric chains, we obtain an apparent melting temperature of 323 K, with a melting Van't Hoff enthalpy of $\Delta H_v = 810 \pm 60$ kJ/mol. This value is in good agreement with the Van't Hoff enthalpy $\Delta H_v \sim 880$ kJ/mol estimated through the equation $\Delta H_v = 4RT_m^2 C_{P,\text{max}} / \Delta H_{\text{cal}}$ from DSC measurements.²⁶ It is also worth of note that, by taking $\Delta H_{\text{cal}} = 443$ kJ/mol,²⁶ it turns out a ratio $\Delta H_v / \Delta H_{\text{cal}} \sim 1.8$: such a value larger than 1 is fully consistent with the unfolding transition coupled to the dimer dissociation.

M^{pro} dimer-monomer equilibrium in presence of inhibitors

In-silico inhibitor selection

To identify new inhibitors of SARS-CoV-2 main protease from a large *in house* database, we applied the *in silico* protocol, recently proposed by some of us.²⁸ The flowchart of the adopted protocol is depicted in Supplementary Fig. S1. As a first step, we performed molecular docking studies on the compounds present in the database to analyze their binding capability in the catalytic active site of the SARS-CoV-2 M^{pro} (PDB code 6y2f),⁷ as detailed in the Materials and Methods section. Supplementary Fig. S2 shows the 3D binding active site of SARS-CoV-2 M^{pro} co-crystallized with the native inhibitor **13b**⁷ covalently bonded to Cys145. The ligand binds to the enzymatic catalytic cleft of the protease located between domains I and II. The 3D binding site representation (Supplementary Fig. S2) highlights the interactions with the amino acid residues involved in the inhibition mechanism, such as Met49, Met165, Glu166, His164, Phe140, Gly143 and the catalytic Cys145. It is noteworthy the presence of hydrogen bonds between the pyridone moiety of ligand and Glu166, which rules the catalytic activity driving the SARS-CoV-2 M^{pro} to adopt an inactive conformation. The resulting best docked molecules have been selected based on a docking score cut-off of -6.5 kcal/mol and submitted to ligand based approaches, by taking advantage of the web-service DRUDIT (DRUGs Discovery Tools), an open access virtual screening platform recently developed,²⁹ which represents the evolution of previous well-established protocols based on molecular descriptors.^{30,31}

DRUDIT implements the ligand based template of SARS-CoV-2 M^{pro}, available in the Biotarget Finder tool, which has been recently proposed as a useful mean in the identification of new SARS-CoV-2 M^{pro} modulators. Subsequently, the ligands

selected by molecular docking were submitted to DRUDIT, as elsewhere reported,²⁸ allowing the evaluation of their affinity to SARS-CoV-2 M^{pro} by the values of Drudit Affinity Score (DAS). The features of the ligand-based approaches based on molecular descriptors allowed the evaluation of topological, thermodynamic and charge-related characteristics of the ligands. Thus, two complementary standpoints in the evaluation of the binding capability (ligand- and structure-based) covered all the interaction aspects in the ligand-target complex. The top scored molecules (selected based on a DAS cut-off of 0.65) were processed by Induced Fit Docking (IFD) calculations to further screen the hits to submit to *in-wet* test. In Supplementary Fig. S3 and in Table 2 the seven best scored structures are reported. Fig. 3 reports the first two best scored molecules **3** and **7**

Inhibitor	Prime_Energy	XPG_score	IFD_score
1	-11527.6	-8.580	-584.958
2	-11360.0	-10.772	-578.774
3	-11674.5	-7.895	-591.618
4	-11497.2	-5.969	-580.827
5	-11517.1	-8.918	-584.772
6	-11489.6	-9.176	-583.655
7	-11561.2	-10.409	-588.468
13b	-11736.3	-7.944	-594.758

Table 2. IFD results for the seven selected inhibitors compared with the **13b** compound.

(according to the IFD_score parameter) in the binding site (left panel) and their related amino-acid maps (right panel). The two molecules are deeply buried in the cleft of the substrate-binding pocket, but unlike the co-crystallized ligand **13b**, they interact with a somehow different pattern of amino-acids. This evidence suggests that these compounds are not covalently bound to the SARS-CoV-2 M^{pro} catalytic site.

M^{pro} activity assays

The selected inhibitors have been tested for their efficacy to reduce the M^{pro} activity. As reported in Fig. 4, the time dependence of substrate fluorescence after hydrolysis indicates that the catalytic activity of M^{pro} in the presence of the selected compounds changes. In particular, compounds **2**, **4**, **5** and **7** induced an irreversible inactivation of the enzyme, while compounds **1** and **6** resulted rather inactive. For two of the most effective compounds (**2** and **7**) inhibition tests have been carried out as a function of the concentration. Unfortunately, we have not been able to perform this test for compound **4**, which shows the best inhibition efficacy, as it produces a fluorescence signal that partially obscures that of the substrate. Results are shown in Fig. 5 (left panel). Percent inhibition data have been fitted with the Hill equation, $p(C_1) = 100/(1 + (IC_{50}/C_1)^n)$, to get the half maximal effective concentration, IC₅₀, and the Hill slope n . We obtained IC₅₀ = 10.3 ± 0.2 μM for **2** and 15 ± 2 μM for **7**, with $n = 5 ± 1$ and 3 ± 1, respectively. These values on n larger than one indicate that the binding is positively cooperative, in agreement with other recent experimental results.³²

SAXS

SAXS curves of SARS-CoV-2 M^{pro} samples obtained in the presence of the seven selected potential inhibitors at two concentrations and at different temperatures are reported in Fig. 1, bottom panels. as log-log plots. SAXS data have been analysed with the same approach adopted for data without inhibitors, with the further assumption that, for each compound, the thermodynamic parameters are linear functions of its concentration C_1 , namely $\Delta G_D^\circ = \Delta G_{D,0}^\circ(1 + \alpha_G C_1)$, $\Delta C_{pD} = \Delta C_{pD,0}(1 + \alpha_{C_p} C_1)$, and $\Delta S_D^\circ = \Delta S_{D,0}^\circ(1 + \alpha_S C_1)$. The three terms $\Delta G_{D,0}^\circ = -RT_0 \log K_{D,0}^\circ$, $\Delta C_{pD,0}$ and $\Delta S_{D,0}^\circ$ are exactly the values already obtained from the analysis of SAXS data without inhibitors (reported in Table 1), and the three corresponding constant rates α_G , α_{C_p} and α_S are fitting parameters common to all the SAXS curves corresponding to the same inhibitor. The high quality of the fitting procedure can be appreciated in Fig. 1 (bottom panels), where the calculated SAXS curves are superposed to the experimental curves and the resulting thermodynamic common fitting parameters are shown in Table 3, first panel. The inhibitors with the lowest values of α_G (Table 3, first panel) are those that mostly favour dimer dissociation. Results reported in Table 3 suggest that compounds **1**, **6**, and **7** are, within the experimental error, mostly able to increase the dissociation equilibrium constant, which at $C_1 = 30 \mu\text{M}$ becomes as large as $\approx 15 \mu\text{M}$ and, at $C_1 = 60 \mu\text{M}$ almost doubles its value, reaching $\approx 30 \mu\text{M}$. Inhibitor **5** is slightly less active: at $C_1 = 60 \mu\text{M}$ we found a dissociation equilibrium constant of $\approx 20 \mu\text{M}$. The other three compounds, **2**, **3** and **4**, do not show any statistically significant difference with respect to the results in the absence of inhibitors. Despite the high uncertainties on α_{C_p} and α_S , their negative values suggest that upon dissociation there are changes of heat capacity and of entropy smaller than those observed without inhibitors, indicating that inhibitors increase the monomer order. Looking to the single curve parameters, reported in Supplementary Table S1 and Supplementary Table S2, we observe that for almost all cases the values of the correlation length ξ are similar for samples with and without inhibitors. The fractal dimension is ≈ 2 , suggesting a two-dimensional fractal growth of the protein clusters in presence of inhibitors.




Figure 3. 3D binding modes of best scored compounds **3** and **7** into SARS-CoV-2 M^{pro} active site (**left**) and corresponding amino acid maps (**right**).

Discussion

It is widely known that the active site of M^{pro} monomer, which is widely conserved among all coronavirus, is typically composed of four subsites, referred to as S1', S1, S2, and S4.^{33–35} They accommodate the corresponding domains P1', P1, P2, and P4 of the substrate or the ones of the inhibiting compound that mimics the substrate.³⁶ The S1' subsite is constituted by the two residues Thr24 and Thr25. The S1 subsite (also referred to as the S1 pocket³⁵) is formed by the side chains of residues Phe140, Asn142, Glu166, His163 and His172 and by the main chains of Phe140 and Leu141.³⁶ As discussed by Sacco et al.,³⁵ there are evidences that S1 can interact with both hydrophobic and hydrophilic groups: hence it is considered a promising target for an inhibiting compound. S2 is a hydrophobic subsite formed by the side chains of His41, Met49, Tyr54, Met165 and Asp187. S4 is a small hydrophobic pocket that involves the side chains of Met165, Leu167, Phe185, Gln192 and Gln189.³⁶ An unusual catalytic dyad, His41-Cys145, acts in the active site, where His41 is a proton acceptor whereas Cys145 is attacked by the carbonyl carbon of the substrate. Hence, a signature of the inhibiting power of a compound is its capability to form a covalent bond with Cys145,³³ as very recently confirmed by Dai et al.,³⁴ who have found two promising inhibitors **11a** and **11b**. The importance of the protonation state of Cys145 as well as the network of hydrogen bonds between the catalytic site of M^{pro} and inhibiting compounds has also been recently discussed by Kneller et al.³⁷ by combining X-ray and neutron results.

On these grounds, the experimental results obtained by the present study, together with the structure of the seven inhibitors within the M^{pro} active site determined by the refined molecular docking, can be discussed.

The interaction map of inhibitor **1** is shown in Supplementary Fig. S4. There are a total of 11 contacts with amino acids of M^{pro} monomer (Ser1, Thr25, Thr26, Ser46, Asn119, Leu141, Asn142, Cys145, Pro168, Arg188, Gln192), 2 of them (Ser46, Asn119) are hydrogen bonds. The residues of the catalytic dyad and the four subsites in contact with **1** are: Cys145 (dyad, 1 of 2 (50%)); Thr25 (S1', 1 of 2 (50%)); Leu141 and Asn142 (S1, 2 of 6 (33%)); Gln192 (S4, 1 of 5 (20%)). To note, these contacts involve only one of the residues of the catalytic dyad, Cys145, without a hydrogen bond, whereas for inhibitor **13b**




Figure 4. Fluorescence inhibition curves of the selected compounds, as indicated in each frame. The straight lines are the best fitting lines obtained considering data points comprised between the time indicated by the arrow and 30 min. The slope of the straight line is reported in each frame.

there is a hydrogen bond with Cys145 (Supplementary Fig. S2). It also worth to notice that Ser1 is among the residue in contact with inhibitor **1**: since the mutual interaction of Glu166 of one monomer and Ser1 (the N-finger) of the other monomer has been proven to shape the catalytic cleft,⁷ we argue that this compound could destabilize the dimer, as suggested by the high value of $K_D^o = 26 \pm 4 \mu\text{M}$ at $C_I = 60 \mu\text{M}$. However, its enzymatic inhibition is very poor, as shown by the high similarity of the RFU slope with the one in the absence of inhibitors (Fig. 4). A possible explanation of this result could be the absence of any hydrogen bond with Cys145 as well as the absence of any contact with the residues of subsite S2.

Regarding inhibitor **2**, the map of contacts shown in Supplementary Fig. S5 reveals a total of 10 interactions with the monomer chain (Met49, Asn142, Gly143, Cys145, Asp187, His164, Met165, Glu166, Arg188, Gln189); 4 of them are hydrogen bonds (Asn142, His164, Glu166, Gln189) that do not involve the catalytic site. More in detail, the residues of the catalytic dyad and the four subsites in contact with **2** are: Cys145 (dyad, 1 of 2 (50%)); Asn142 and Glu166 (S1, 2 of 6 (33%)); Met49, Met165 and Asp187 (S2, 3 of 5 (60%)); Met165 and Gln189 (S4, 2 of 5 (40%)). We also note that 2 residues of S1, Asn142 and Glu166, interact with this inhibitor via a hydrogen bond. This evidence, together with the high number of contacts with S2 and S4, could explain the experimentally observed inhibition effect ($m = 5 \pm 2$ RFU/min, Fig. 4). To note, this compound does not modify the dimer-monomer equilibrium (Table 3) and shows the worst IFD_score parameter (Table 2).

Turning now to inhibitor **3**, despite it shows one of the best performance in terms of IFD_score (Table 2), we have found that it does not alter the native dissociation equilibrium of $\text{MP}^{\text{P}10}$ (Table 3) and also his inhibition effect observed by fluorescence analysis is weak ($m = 23 \pm 3$ RFU/min, slightly lower than the value in absence of inhibitors). The contact map of compound **3** (Fig. 3) show a total of 12 interactions with the monomer chain (Thr24, Thr25, Thr26, His41, Ser46, Met49, Phe140, Leu141, Gly143, Met165, Leu167, Gln192), 2 of them being hydrogen bonds (Thr24, Ser46) and one (His41) a $\pi - \pi$ stacking. The residues of the catalytic dyad and the four subsites in contact with **3** are: His41 (dyad, 1 of 2 (50%)); Thr24 and Thr25 (S1', 2 of 2 (100%)); Phe140 and Leu141 (S1, 2 of 6 (33%)); His41, Met49 and Met165 (S2, 3 of 5 (60%)); Met165, Leu167 and Gln192 (S4, 3 of 5 (60%)). We notice that with respect to compound **2**, there are not hydrogen bonds with the five residues that

Inhibitor	α_G ($10^{-2} \mu\text{M}^{-1}$)	α_{C_p} ($10^{-2} \mu\text{M}^{-1}$)	α_S ($10^{-2} \mu\text{M}^{-1}$)
1	-0.18 ± 0.02	-6 ± 3	-4 ± 1
2	-0.0 ± 0.1	-1 ± 3	-4 ± 1
3	0.00 ± 0.08	0 ± 4	-8 ± 4
4	0.0 ± 0.1	-2 ± 2	-1 ± 5
5	-0.14 ± 0.05	-1 ± 4	-4 ± 4
6	-0.20 ± 0.05	-6 ± 3	-1.7 ± 0.8
7	-0.19 ± 0.07	-3 ± 3	-5 ± 2

30 μM Inhibitor	1	2	3	4	6	7
K_D° (μM)	14 ± 1	8 ± 3	7 ± 2	6 ± 2	15 ± 3	14 ± 3

60 μM Inhibitor	1	2	3	4	5	6	7
K_D° (μM)	26 ± 4	8 ± 6	7 ± 4	5 ± 4	19 ± 7	30 ± 10	30 ± 10

Table 3. Top panel: common thermodynamic fitting parameters of the analysis of SAXS data for SARS-CoV-2 M^{pro} samples with inhibitors. **Middle and bottom panels:** dissociation constants derived by the analysis of SAXS data for SARS-CoV-2 M^{pro} samples with inhibitors.

stabilize the S1 pocket. This difference might be the reason for the weak inhibition effect.

Compound **4** is the most effective among the seven inhibitors ($m \approx 0$, Fig. 4), with a K_D° slightly lower than the one without inhibitors (Table 3). The contact map (Supplementary Fig. S6) shows 11 interactions with the monomer chain (Thr25, Thr26, Leu27, His41, Ser46, Met165, Glu166, Pro168, Gln189, Thr190, Gln192), including one hydrogen bond (Gln189). The residues of the catalytic dyad and the four subsites in contact with **4** are: His41 (dyad, 1 of 2 (50%)); Thr25 (S1', 1 of 2 (50%)); Glu166 (S1, 1 of 6 (17%)); His41 and Met165 (S2, 2 of 5 (40%)); Met165, Gln192 and Gln189 (S4, 3 of 5 (60%)). Only one of the five residues that stabilize the S1 pocket is among the ones in contact with this inhibitor, Glu166, which does not form a hydrogen bond. On this ground, the high inhibition effect of compound **4** could be only justified by the contact with His41, one of the two residues of the catalytic dyad.

Results are different for compound **5**: it provokes a rather important increase of K_D° (Table 3) and shows a moderate inhibition effect ($m = 8 \pm 3$ RFU/min). Looking at the interaction map (Supplementary Fig. S7), we notice 11 interactions with monomer M^{pro} (Thr25, Thr26, Leu27, His41, Asn142, Gly143, Met165, Glu166, Pro168, Arg188, Gln192), one of them regards Glu166, involved in two hydrogen bonds, and the other one His41, involved in two a $\pi - \pi$ stacking interactions. The residues of the catalytic dyad and the four subsites in contact with **5** are: His41 (dyad, 1 of 2 (50%)); Thr25 (S1', 1 of 2 (50%)); Asn142 and Glu166 (S1, 2 of 6 (33%)); His41 and Met165 (S2, 2 of 5 (40%)); Met165 and Gln192 (S4, 2 of 5 (40%)). There are not hydrogen bonds involving the five residues that stabilize the S1 site. One could speculate that this inhibitor, probably due to its steric hindrance, provokes a modification of S1 that could interfere with the enzymatic activity of M^{pro}.

Compound **6** determines 11 contacts with the amino acid of the monomer (His41, Leu141, Ser144, Cys145, Met165, Glu166, Leu167, Arg188, Gln189, Ala191, Gln192, Supplementary Fig. S8), including two hydrogen bond (His41, Gln192). In particular, the residues of the catalytic dyad and the four subsites in contact with **6** are: His41 and Cys145 (dyad, 2 of 2 (100%)); Leu141 and Glu166 (S1, 2 of 6 (33%)); His41 and Met165 (S2, 2 of 5 (40%)); Met165, Leu167, Gln192 and Gln189 (S4, 4 of 5 (80%)). An almost absent inhibition effect is seen by fluorescence, being the slope of RFU (Fig. 4) very similar to the one determined in the absence of inhibitors. On the other side, compound **6** is able to modify the dimer-monomer dissociation, with one of the highest value of $K_D^\circ = 30 \pm 10 \mu\text{M}$ at $C_1 = 60 \mu\text{M}$ (Table 3). To note, only one of the 6 amino acids that stabilize the S1 site are included in the list of residues interacting with compound **6**. Hence, the absence of its inhibition activity could be explained by the small size of its molecular structure, which might not be able to provoke important modifications of the S1 pocket and hence to modify the catalytic features of M^{pro}.

We finally turn to compound **7**, which reports the best value of IFD_score (Table 2). It shows an opposite behaviour with respect to compound **6**: it is capable to change the dimer-monomer equilibrium at the same extent ($K_D^\circ = 30 \pm 10 \mu\text{M}$ at $C_1 = 60 \mu\text{M}$, Table 3) and displays a promising inhibition effect, with $m \approx 1$. For this compound, the map of contacts shows 12 interactions (Thr24, Thr25, Thr26, His41, Thr45, Met49, Leu141, His164, Met165, Glu166, Asp187, Arg188, Fig. 3) with a large number of hydrogen bonds (Thr24, Thr26, His41, His164, Glu166, Arg188). The residues of the catalytic dyad and the four subsites in contact with **7** are: His41 (dyad, 1 of 2 (50%)); Thr24 and Thr25 (S1', 2 of 2 (100%)); Leu141 and Glu166 (S1, 2 of 6 (33%)); His41, Met49, Met165 and Asp187 (S2, 4 of 5 (80%)); Met165 (S4, 1 of 5 (20%)). Only one of the interacting

residues (Glu166) is involved in the stabilization of the S1 pocket. We can argue that the high inhibition effect could be due to the high number of contact with S2 and to the presence of the 6 hydrogen bonds. An other hypothesis, which needs further insights to be confirmed, is that the fluorinated groups, which are present in a high number in compound **7**, may originate a new reactive warhead able to form a covalent bond with Cys145. We may also consider that one of them involves a residue of the catalytic dyad, His41, suggesting a possible important modification of the enzymatic activity.

In summary, our results show that the inhibition effect of compounds designed to bind the catalytic site of SARS-CoV-2 M^{Pro} does not necessarily modify the dimer-monomer equilibrium. On the other side, we have also observed that compounds able to provoke dissociation do not always show inhibition effects. To better visualize the scenario presented by our results, we report in Fig. 5 (right panel) the slope m of the fluorescence inhibition curve as a function of the dimer-monomer equilibrium constant K_D^0 obtained at $C_I = 60 \mu\text{M}$ for the seven compounds. The points in this map could be organized in two groups, as represented in blue and in red. The red points refer to compounds that show an expected behaviour: the strongest is their capability to induce the dissociation of the M^{Pro} dimer, the most important is their inhibition effect. For the blue compounds, the behavior is opposite: the increasing of the dissociation does not determine an increase of the inhibition effect. This apparently contradictory result can be in part explained by considering that, in all cases, the dissociation equilibrium is weak. As clearly shown in Supplementary Table S2 the fraction of monomers x_1 is never larger than ≈ 0.6 , even in the case of the most effective among our compounds. This means that, in the presence of a compound that alter the dimer-monomer equilibrium but that does not hamper the interaction with the substrate, there are always dimeric M^{Pro} molecules that can exert their enzymatic activity when a substrate is available.

Very recently Suárez et al.,³⁸ through a $2 \mu\text{s}$ Molecular Dynamics simulation of M^{Pro} with and without a model peptide mimicking the enzyme substrate, have shown the importance of the dimerization in stabilizing the catalytic dyad and the overall contribution of protein flexibility in the binding of the protein with the substrate. The experimental work presented here provides a further evidence on the complex interplay between enzymatic activity inhibition and dimer dissociation. Furthermore, at the best of our knowledge, it shows for the first time the contribution of the SAXS technique, combined with advanced data analysis, for obtaining structural information about the SARS-CoV-2 M^{Pro} in solution and in the presence of promising inhibitors. Our results suggest that more experimental evidences about the impairment of monomer and dimer M^{Pro} in the presence of inhibitors corroborated by computational result will be necessary for a deeper understanding of the M^{Pro} allosteric mechanism.




Figure 5. Left: percent inhibition data of SARS-CoV-2 M^{Pro} as a function of the concentration of inhibitor **2** (green points) and **7** (magenta points). Best fits with the Hill equation are shown as solid lines. Right: correlation map between the catalytic activity, represented by the RFU slope m , and dimer dissociation capability, measured by the dissociation constant K_D^0 , of the seven SARS-CoV-2 M^{Pro} inhibitors.

Materials and Methods

M^{Pro} expression and western blot analysis

pGEX-6P-1 vector harboring the full length cDNA sequence encoding for SARS-CoV-2 Main Protease (M^{Pro} NC_045512) was purchased from GenScript (clone ID_M16788F). The expressing vector was transformed into BL21DE3pLys *Escherichia*

coli cells and the obtained clones were assayed both in small scale (5 mL) and medium scale (500 mL and 1 L) for the production of SARS-CoV-2 M^{pro}. Transformants were grown onto LB medium containing 100 µg/mL Ampicillin and 34 µg/mL Chloramphenicol as selective antibiotics. Cultures were grown up to OD600 of 0.6-0.8 at 37° C, 200 rpm and then M^{pro} expression was induced by addition of 0.5 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG). Growth under induction was achieved both for 3 h at 37° C and 10 h at 16° C in order to test the best expressing condition. Cells were harvested by centrifugation at 6000 g. Cell pellets were resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM β-mercaptoethanol), and cell rupture was achieved by sonication (Sonic Vibra Cell sonicator) at 4° C. Cell debris was separated from the total protein extract by centrifugation at 6500 g for 1 h. Supernatant aliquotes were resuspended in Laemmli sample buffer, run onto 12% SDS-PAGE and transferred onto PVDF membrane for Western blot analysis. M^{pro} was decorated by 6×-His tag monoclonal primary antibody (Invitrogen) and anti-mouse secondary antibody and detected by chemiluminescence (ClarityTM Western ICL Substrate, Biorad, Supplementary Fig. S10, panels A and B).

M^{pro} purification and His-tag cleavage

The total cell extract was loaded onto Ni-NTA affinity column (G-Biosciences) and washed by washing buffer (Tris-HCl 20 mM pH 7.6, NaCl 100 mM). M^{pro} was eluted by elution buffer (Tris-HCl 20 mM pH 7.6, NaCl 100 mM, 300 mM imidazole) in 5 fractions of 1 mL each. Aliquotes of elution fractions were loaded onto 12% SDS-PAGE acrylamide gel and imidazole was removed by dialysis against Precision cleavage buffer (Tris-HCl 50 mM pH 8.0, NaCl 150 mM, DTT 1 mM, EDTA 1 mM) through Amicon Ultra-4 centrifugal filters 30K (Merck Millipore). For M^{pro} C-terminal His-tag removal, the Precision (1 U for 100 µg of protein) cleavage reaction was performed at 4° C for 4 h and Precision protease was then removed by GSTrap FF column (GE-Healthcare). The M^{pro} solution was further purified by FPLC size-exclusion chromatography on SuperdexTM 75 10/300 GL column (Supplementary Fig. S9, panels A and B).^{26,36}

M^{pro} activity assay and inhibition

The fluorescently labelled auto-cleavage sequence of SARS-CoV-2 M^{pro}, Mca-AVLQ↓SGFRK(Dnp)K (purchased from GenScript), was utilized to monitor the recombinant M^{pro} kinetics (excitation 320 nm, emission 405 nm). The assay was started by mixing ≈ 0.2 µM SARS-CoV-2 M^{pro} to different amounts of substrate (10, 20, 40 µM) in order to set the best protein-substrate concentration to detect M^{pro} activity.³³ Fluorescence intensity was measured by DeNovix DS-11 FX+ fluorometer. The M^{pro} activity reported as reference for inhibition tests was obtained by linear fitting of the fluorescence curve in the presence of 40 µM of substrate concentration.^{26,33} Seven inhibitors dissolved in DMSO were tested at a final concentration of 30 µM³⁴ (Fig. 4). Each reaction in a final volume of 200 µL was firstly incubated for 20 min at 30° C without substrate. After substrate addition, fluorescence intensities were reported as relative fluorescence units (RFU) and monitored every minute for a duration of 30 min at 30° C.

Circular Dichroism

Circular dichroism measurements were performed using Jasco J810 spectropolarimeter. Quartz cuvettes with path-length of 1 mm was used, in order to obtain the optimum signal-to-noise ratio for the M^{pro} samples with concentrations of 16, 6 and 2.5 µM respectively. Each spectrum was collected in the range from 220 to 325 nm, with a scan speed of 50 nm/min. The thermal stability has been studied at 16 µM M^{pro} concentration, by varying the temperature through a thermal bath from 300 to 350 K.

Small Angle X-ray Scattering

SAXS experiments were carried out at the B21 beam-line of the Diamond Synchrotron (Didcot, UK), operating with a fixed camera length (4.014 m) at 12.4 keV ($\lambda = 1.000 \text{ \AA}$) and with a flux of $\sim 10^{12}$ photons per second. Samples were injected in the capillary (thickness 1.7 mm) by means of a robotic apparatus and measured 21 times with an exposure time of 1 min. The M^{pro} samples without inhibitors were measured at the nominal monomer molar concentration of 3, 10, 20 and 30 µM and at temperature of 15°, 25°, 30°, 37° and 45° C. In the presence of inhibitors, SAXS curves were recorded at two M^{pro} monomer molar concentration, 30 and 60 µM, and at three temperatures, 30°, 37° and 45° C.

SAXS data analysis approach has been described in the main text, with the exception of some minor points. Since in all conditions the nominal molar protein concentration is lower than 1 mM, its temperature variations can be considered to be only determined by the dependency with T of the relative mass density of water, which, according to literature results³⁹ is written as

$$d_w = e^{-\alpha_w(T-T_0)-\beta_w(T-T_0)^2/2}, \quad (9)$$

where, in our investigated range 15 – 45° C, the optimum value of the thermal expansivity at T_0 is $\alpha_w = 2.5 \cdot 10^{-4} \text{ K}^{-1}$ and the one of its first derivative is $\beta_w = 9.8 \cdot 10^{-6} \text{ K}^{-2}$. Accordingly, $C_N = C_0 d_w$, C_0 being the nominal protein concentration at T_0 .

The measured structure factor $S_M(q)$ has been obtained in relation to the protein-protein structure factor $S(q)$ by:

$$S_M(q) = 1 + \beta(q)[S(q) - 1] \quad (10)$$

where $\beta(q)$ is the coupling function

$$\beta(q) = \frac{|P^{(1)}(q)|^2}{P(q)} \quad (11)$$

and $P^{(1)}(q)$ is the average of the protein excess scattering amplitude, a function provided, together with $P(q)$ by the SASMOL method. According to Ref.,¹⁶ $S(q)$ has been written as

$$S(q) = 1 + \frac{1}{(qr_0)^D} \frac{D\Gamma(D-1)}{[1 + (q\xi)^{-2}]^{D(D-1)/2}} \sin[(D-1)\tan^{-1}(q\xi)], \quad (12)$$

where $\Gamma(x)$ is the gamma function, D is the fractal dimension (comprised between 1 and 3) of the aggregates, r_0 is the effective radius of the aggregating protein and ξ is the correlation length.

In-silico design

Ligand Preparation

The default setting of the LigPrep tool implemented in Schrödinger's software (version 2017-1) was used to prepare the ligands for docking.⁴⁰ All possible tautomers and combination of stereoisomers were generated for pH 7.0 ± 0.4 , using the Epik ionization method.⁴¹ Energy minimization was subsequently performed using the integrated OPLS 2005 force field.⁴²

Protein Preparation

The crystal structure of SARS-CoV-2 M^{PRO} in complex with ligand **13b** (PDB code 6y2f)⁷ was downloaded from the Protein Data Bank.⁴³ The cocrystal ligand, covalently bonded to Cys145, was treated by breaking the covalent bond and filling in open valence. Protein Preparation Wizard of Schrödinger software was subsequently employed for further preparations of the protein structure using the default settings.⁴⁴ Bond orders were assigned, and hydrogen atoms as well as protonation of the heteroatom states were added using the Epik-tool (with the pH set at biologically relevant values, i.e. at 7.0 ± 0.4). The H-bond network was then optimized. The structure was subjected to a restrained energy minimization step (RMSD of the atom displacement for terminating the minimization was 0.3 \AA), using the Optimized Potentials for Liquid Simulations (OPLS) 2005 force field.⁴²

Docking Validation

Molecular Docking was performed by the Glide program.^{30,45,46} The receptor grid preparation was performed by assigning the original ligand (**13b**) as the centroid of the grid box. The generated 3D conformers were docked into the receptor model using the Standard Precision (XP) mode as the scoring function. A total of 5 poses per ligand conformer were included in the post-docking minimization step, and a maximum of 2 docking poses were generated for each ligand conformer. The proposed docking procedure was validated by the re-dock of the crystallized **13b** within the receptor-binding pockets of 6y2f by Glide covalent docking. The results obtained were in good agreement of the experimental poses, showing a RMSD of 0.75 \AA .

Biotarget Finder module (DRUDIT)

The refined selection of suitable SARS-CoV-2 M^{PRO} inhibitors was performed through the module Biotarget Finder as available in the www.drudit.com webserver.²⁹ The tool allows to predict the binding affinity of candidate molecules versus the selected biological target. The template of the biological target was built as previously reported. Thus, the in house database was submitted to the Biological Predictor module by setting the DRUDIT parameters, N , Z , and G , using the crystallized structure of **13b**, as previously reported.²⁸

Induced Fit Docking

Induced fit docking simulation was performed using the IFD application as available^{31,47} in the Schrödinger software suite,⁴⁸ which has been demonstrated to be an accurate and robust method to account for both ligand and receptor flexibility.⁴⁹ The IFD protocol was performed as follows:^{50,51} the ligands were docked into the rigid receptor models with scaled down van der Waals (vdW) radii. The Glide Standard Precision (XP) mode was used for the docking and 20 ligand poses were retained for protein structural refinements. The docking boxes were defined to include all amino acid residues within the dimensions of $25 \text{ \AA} \times 25 \text{ \AA} \times 25 \text{ \AA}$ from the centre of the original ligands. The induced-fit protein-ligand complexes were generated using Prime software.^{52,53} The 20 structures from the previous step were submitted to side chain and backbone refinements. All residues with at least one atom located within 5.0 \AA of each corresponding ligand pose were included in the refinement by Prime. All the poses generated were then hierarchically classified, refined and further minimized into the active site grid before being finally scored using the proprietary GlideScore function defined as follows: $XPG_score =$

0.065 vdW + 0.130 Coul + Lipo + Hbond + Metal + BuryP + RotB + Site, where vdW is the van der Waals energy term, Coul is the Coulomb energy, Lipo is a lipophilic contact term that rewards favourable hydrophobic interactions, Hbond is an H-bonding term, Metal is a metal-binding term (where applicable), BuryP is a penalty term applied to buried polar groups, RotB is a penalty for freezing rotatable bonds and Site is a term used to describe favourable polar interactions in the active site. Finally, IFD_score (IFD_score = XPG_score + 0.05 Prime_Energy), which accounts for both protein-ligand interaction energy and total energy of the system, was calculated and used to rank the IFD poses. More negative IFD_score values indicated more favourable binding. Results are shown in Table 2.

Chemical synthesis of inhibitors

Inhibitors **1**,⁵⁴ **3**,⁵⁴ **5**⁵⁴ and **6**⁵⁵ have been prepared as previously reported. Inhibitor **2** is commercial. Inhibitors **4**⁵⁴ and **7**⁵⁴ have been synthesized as described in detail in the next paragraphs. All solvent and reagents were used as received, unless otherwise stated. Melting points were determined on a hot-stage apparatus. ¹H-NMR and ¹³C-NMR spectra were recorded at indicated frequencies, residual solvent peak was used as reference. Chromatography was performed by using silica gel (0.040-0.063 mm) and mixtures of ethyl acetate and petroleum ether (fraction boiling in the range of 40-60° C) in various ratios (v/v). Compounds **8**⁵⁴ and **9**,⁵⁶ used in the synthesis of inhibitors **4** and **7**, have been prepared as previously reported.

Synthesis of inhibitor 4

Inhibitor **4** was synthesized through a nucleophilic aromatic substitution (S_NAr) of 5-pentafluorophenyl-1,2,4-oxadiazole **8** with 1-Aza-18-crown-6 in para position (Supplementary Fig. S11). Oxadiazole **8** (312 mg, 1 mmol) was dissolved in acetonitrile (5 mL). 1-Aza-18-crown-6 (289 mg, 1.1 mmol) and potassium carbonate (152 mg, 1.1 mmol) were added and the suspension was stirred at room temperature for 24 h. The reaction was monitored by TLC. The reaction mixture was dried under vacuum and treated with H₂O (50 mL) before extraction three times with EtOAc (50 mL each). The combined organic layers were dried with Na₂SO₄ and then concentrated in vacuo to give the crude product, which was recrystallized from EtOH. **16-(2,3,5,6-tetrafluoro-4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl)-1,4,7,10,13-pentaoxa-16-azacyclooctadecane**: yield: 73%. m.p.: 60-62° C. ¹H-NMR (250 MHz, CDCl₃) δ: 3.68-3.80 (m, 24H, overlapped -CH₂- signals), 7.51-7.54 (m, 3H, Ar), 8.16-8.20 (m, 3H, Ar). FTIR (Nujol) 1647, 1529, 1518 cm⁻¹; HRMS-ESI [(M+H)⁺]: *m/z* calculated for (C₂₆H₃₀F₄N₂O₆)⁺: 556.2060; found, 556.2046.

Synthesis of inhibitor 7

Tripodal oxadiazolylamide (inhibitor **7**) was easily obtained by means of nucleophilic displacement with ethylamine from tripodal ester **9**, which was previously reported as heavy metal fluorescent sensor (Supplementary Fig. S12).⁵⁶ Tripodal **9** (101 mg, 0.1 mmol) was dissolved in acetonitrile (3 mL). Ethylamine (2 M in MeOH, 150 μL, 0.3 mmol) was added and the solution was stirred at room temperature for 24 h. The reaction was monitored by TLC. The reaction mixture was dried under vacuum and treated with H₂O (50 mL) before extraction three times with EtOAc (50 mL each). The combined organic layers were dried with Na₂SO₄ and then concentrated in vacuo to give the crude product, which was purified by chromatography. **5,5',5''-(((nitriлотris(ethane-2,1-diyl))tris(azanediy))tris(2,3,5,6-tetrafluorobenzene-4,1-diyl))tris(N-ethyl-1,2,4-oxadiazole-3-carboxamide)**: yield: 66%. m.p.: 188-189° C. ¹H-NMR (300 MHz, DMSO-*d*₆) δ: 1.18 (t, 9H, *J* = 6.9 Hz, CH₃), 2.85 (bs, 6H, NCH₂CH₂NH-), 3.34-3.48 (m, 6H, CH₃CH₂NH-), 3.56 (bs, 6H, NCH₂CH₂NH-), 6.91 (bs, 3H, NCH₂CH₂NH-), 9.02 (t, 3H, *J* = 5.7 Hz, NHCH₂CH₃). FTIR (Nujol) 3325, 1701, 1680, 1647 cm⁻¹; HRMS-ESI [(M+H)⁺]: *m/z* calculated for (C₃₉H₃₄F₁₂N₁₃O₆)⁺: 1007.2485; found, 1007.2518.

References

1. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. *Lancet* **395**, 470–473 (2020).
2. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270+ (2020).
3. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. & Hilgenfeld, R. Coronavirus main proteinase (3CL(pro)) structure: Basis for design of anti-SARS drugs. *Science* **300**, 1763–1767 (2003).
4. Morse, J. S., Lalonde, T., Xu, S. & Liu, W. R. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. *ChemBioChem* **21**, 730–738 (2020).
5. Zhang, D. *et al.* Evolutionary selection associated with the multi-function of overlapping genes in the hepatitis B virus. *Infection genetics and evolution* **10**, 84–88 (2010).
6. Goyal, B. & Goyal, D. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. *ACS Combinatorial Science* **22**, 297–305 (2020).

7. Zhang, L. *et al.* Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. *Science* **368**, 409–412 (2020).
8. Shi, J. & Song, J. The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain. *FEBS Journal* **273**, 1035–1045 (2006).
9. Anand, K. *et al.* Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. *Embo Journal* **21**, 3213–3224 (2002).
10. Chen, S. *et al.* Severe acute respiratory syndrome coronavirus 3C-like proteinase n terminus is indispensable for proteolytic activity but not for enzyme dimerization - Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations. *Journal of Biological Chemistry* **280**, 164–173 (2005).
11. Chou, C. *et al.* Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. *Biochemistry* **43**, 14958–14970 (2004).
12. Wei, P. *et al.* The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. *Biochemical and Biophysical Research Communications* **339**, 865–872 (2006).
13. Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y. & Jung, S.-H. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. *Journal of Medicinal Chemistry* **59**, 6595–6628 (2016).
14. Spinozzi, F., Ferrero, C., Ortore, M. G., Antolinos, A. D. M. & Mariani, P. GENFIT: software for the analysis of small-angle X-ray and neutron scattering data of macromolecules in-solution. *J. App. Cryst.* **47**, 1132–1139 (2014).
15. Ortore, M. G. *et al.* Combining structure and dynamics: non-denaturing high-pressure effect on lysozyme in solution. *J. R. Soc. Interface* **6**, S619–S634 (2009).
16. Teixeira, J. Small-angle scattering by fractal systems. *J. Appl. Cryst.* **21**, 781–785 (1988).
17. Graziano, V., McGrath, W. J., Yang, L. & Mangel, W. F. SARS CoV Main Proteinase: The Monomer-Dimer Equilibrium Dissociation Constant. *Biochemistry* **45**, 14632–14641 (2006).
18. Apenten, R., Khokhar, S. & Galani, D. Stability parameters for β -lactoglobulin thermal dissociation and unfolding in phosphate buffer at pH 7.0. *Food Hydrocolloids* **16**, 95 – 103 (2002).
19. Janin, J. Elusive affinities. *Proteins: Structure, Function, and Bioinformatics* **21**, 30–39 (1995).
20. Horton, N. & Lewis, M. Calculation of the free energy of association for protein complexes. *Protein Science* **1**, 169–181 (1992).
21. Svergun, D. *et al.* Protein hydration in solution: experimental observation by X-ray, neutron scattering. *Proc. Natl. Acad. Sci. USA* **95**, 2267–2272 (1998).
22. Sinibaldi, R. *et al.* Preferential hydration of lysozyme in water/glycerol mixtures: A small-angle neutron scattering study. *J. Chem. Phys.* **126**, 235101–235109 (2007).
23. Sinibaldi, R. *et al.* Sans/saxs study of the bsa solvation properties in aqueous urea solutions via a global fit approach. *Eur. Biophys. J.* **37**, 673–681 (2008).
24. Greenfield, N. J. & Fasman, G. D. Computed Circular Dichroism Spectra for the Evaluation of Protein Conformation. *Biochemistry* **8**, 4108–4116 (1969).
25. Greenfield, N. J. Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. *Nature Protocols* **1**, 2527–2535 (2006).
26. Abian, O. *et al.* Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. *International Journal of Biological Macromolecules* **164**, 1693 – 1703 (2020).
27. Shi, J., Wei, Z. & Song, J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme - Defining the extra domain as a new target for design of highly specific protease inhibitors. *Journal of Biological Chemistry* **279**, 24765–24773 (2004).
28. Martorana, A., Gentile, C. & Lauria, A. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection. *Viruses* **12**, 805 (2020).
29. Lauria, A. *et al.* DRUDIT: web-based DRUGs DIScovery Tools to design small molecules as modulators of biological targets. *Bioinformatics* **36**, 1562–1569 (2019).

30. Friesner, R. A. *et al.* Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. *Journal of Medicinal Chemistry* **47**, 1739–1749 (2004).
31. Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A. & Farid, R. Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects. *Journal of Medicinal Chemistry* **49**, 534–553 (2006).
32. Lee, J. *et al.* Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. *NATURE COMMUNICATIONS* **11** (2020).
33. Yang, H. *et al.* Design of wide-spectrum inhibitors targeting coronavirus main proteases. *PLOS Biology* **3**, e324 (2005).
34. Dai, W. *et al.* Structure-based design of antiviral drug candidates targeting the sars-cov-2 main protease. *Science* **368**, 1331–1335 (2020).
35. Sacco, M. D. *et al.* Structure and inhibition of the sars-cov-2 main protease reveal strategy for developing dual inhibitors against mpro and cathepsin l. *Science Advances* **6** (2020).
36. Jin, Z. *et al.* Structure of M^{pro} from SARS-CoV-2 and discovery of its inhibitors. *Nature* **582**, 289–293 (2020).
37. Kneller, D. W., Phillips, G., Kovalevsky, A. & Coates, L. Room-temperature neutron and X-ray data collection of 3CL M^{pro} from SARS-CoV-2. *Acta Crystallographica Section F* **76**, 483–487 (2020).
38. Suárez, D. & Díaz, N. Sars-cov-2 main protease: A molecular dynamics study. *JCIM* **0**, null (2020).
39. Kell, G. S. Density, thermal expansivity, and compressibility of liquid water from 0° C to 150° C. Correlations and tables for atmospheric pressure and saturation reviewed and expressed on 1968 temperature scale. *J. Chem. Eng. Data* **20**, 97–105 (1975).
40. Schrödinger Release 2017, N. Y., LLC. LigPrep (2017).
41. Schrödinger Suite 2017-2, N. Y., LLC. Epik, Protein Preparation Wizard (2017).
42. Banks, J. L. *et al.* Integrated Modeling Program, Applied Chemical Theory (IMPACT). *Journal of Computational Chemistry* **26**, 1752–1780 (2005).
43. Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. *Nature Structural Biology* **10**, 980–980 (2003).
44. Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *Journal of Computer-Aided Molecular Design* **27**, 221–234 (2013).
45. Friesner, R. A. *et al.* Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. *Journal of Medicinal Chemistry* **49**, 6177–6196 (2006).
46. Halgren, T. A. *et al.* Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. *Journal of Medicinal Chemistry* **47**, 1750–1759 (2004).
47. Sherman, W., Beard, H. S. & Farid, R. Use of an Induced Fit Receptor Structure in Virtual Screening. *Chemical Biology Drug Design* **67**, 83–84 (2006).
48. Schrödinger Release 2012, N. Y., LLC. Maestro, version 9.3 (2012).
49. Zhong, H., Tran, L. M. & Stang, J. L. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. *Journal of Molecular Graphics and Modelling* **28**, 336–346 (2009).
50. Wang, H., Aslanian, R. & Madison, V. S. Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor 17 α pocket flexibility. *Journal of Molecular Graphics and Modelling* **27**, 512–521 (2008).
51. Luo, H.-J., Wang, J.-Z., Deng, W.-Q. & Zou, K. Induced-fit docking and binding free energy calculation on furostanol saponins from *Tupistra chinensis* as epidermal growth factor receptor inhibitors. *Medicinal Chemistry Research* **22**, 4970–4979 (2013).
52. Jacobson, M. P. *et al.* A hierarchical approach to all-atom protein loop prediction. *Proteins: Structure, Function, and Bioinformatics* **55**, 351–367 (2004).
53. Jacobson, M. P., Friesner, R. A., Xiang, Z. & Honig, B. On the Role of the Crystal Environment in Determining Protein Side-chain Conformations. *Journal of Molecular Biology* **320**, 597–608 (2002).
54. Buscemi, S., Pace, A., Palumbo Piccionello, A. & Vivona, N. Synthesis of fluorinated first generation starburst molecules containing a triethanolamine core and 1,2,4-oxadiazoles. *Journal of Fluorine Chemistry* **127**, 1601–1605 (2006).

55. Martorana, A., Palumbo Piccionello, A., Buscemi, S., Giorgi, G. & Pace, A. Synthesis of 4(5)-phenacyl-imidazoles from isoxazole side-chain rearrangements. *Organic and Biomolecular Chemistry* **9**, 491–496 (2011).
56. Pibiri, I. *et al.* Fluorescent Hg²⁺ sensors: Synthesis and evaluation of a tren-based starburst molecule containing fluorinated 1,2,4-oxadiazoles. *European Journal of Organic Chemistry* **2010**, 4549–4553 (2010).

Acknowledgements

We thank Diamond Light Source for access to beam-line B21 (SM27078) and for the assistance of Charlotte Edwards-Gayle during the SAXS experiments.

Author contributions statement

P.Mariani, L.Si., A.P. and F.S. conceived and designed the work. L.Si., L.Sa. and N.B. synthesised M^{Pro} and performed enzymatic activity assays. A.P., C.P., L.C. and V.L. collected and analysed CD data. A.L. performed docking. F.S., Y.G., P.Mariani and M.G.O. collected and analyzed SAXS data. A.P.P. and P.Marzullo synthesized inhibitors. A.P. and F.S. took overall responsibility for the manuscript. All authors approved the final version of the manuscript.

Figures




Figure 1

SAXS data and fits. Top panels: SAXS experimental data of SARS-CoV-2 Mpro without inhibitors and best theoretical fits obtained by GENFIT software¹⁴ (solid black and white lines). Each panel reports a dataset obtained at the same temperature. Bottom panels: SAXS data of Mpro with inhibitors at different concentrations and temperatures. Each panel reports curves at the same temperature. Red, green, blue, orange, dark-green, cyan and magenta refers to inhibitor 1, 2, 3, 4, 5, 6 and 7, respectively. Thin and thick lines refer to inhibitor concentrations of 30 and 60 mM, respectively. Subsequent curves are multiplied by a factor 3.0 for clarity. Solid black and white lines are the best fits obtained by GENFIT.




Figure 2

CD data and fits. Left: far-UV CD spectra of SARS-CoV-2 Mpro at three different concentrations. Inset: position of the minimum of the spectra as a function of the concentration (red circles). The continuous line represents an estimate of the minimum position based on equation 7. Results from the fit are: $\mu_{min\ mon} = 216:4 \pm 0:1$ nm and $\mu_{min\ dim} = 222:9 \pm 0:1$ nm. Right: Thermal melting of the SARS-CoV-2 Mpro followed by monitoring the far-UV CD signal at 221 nm. The continuous line results from the theoretical fitting model arising from equation 8.




Figure 3

3D binding modes of best scored compounds 3 and 7 into SARS-CoV-2 Mpro active site (left) and corresponding amino acid maps (right).




Figure 4

Fluorescence inhibition curves of the selected compounds, as indicated in each frame. The straight lines are the best fitting lines obtained considering data points comprised between the time indicated by the arrow and 30 min. The slope of the straight line is reported in each frame.




Figure 5

Left: percent inhibition data of SARS-CoV-2 Mpro as a function of the concentration of inhibitor 2 (green points) and 7 (magenta points). Best fits with the Hill equation are shown as solid lines. Right: correlation map between the catalytic activity, represented by the RFU slope m , and dimer dissociation capability, measured by the dissociation constant K_D^0 , of the seven SARS-CoV-2 Mpro inhibitors.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Sl.pdf](#)